SCHEMBL424911

SCHEMBL424911

CN(C(=O)n1cnc(-c2ccc(F)c(O)c2)c1)C1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.48
CES2 O00748 1/20 0.48
PIK3CD O00329 3/20 0.37
PDE4B Q07343 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
TGFBR1 P36897 1/20 0.36
ABL1 P00519 3/20 0.36
PIK3CA P42336 3/20 0.36
MTOR P42345 3/20 0.36
EGFR P00533 2/20 0.36
HCK P08631 2/20 0.36
SRC P12931 2/20 0.36
KDR P35968 2/20 0.36
PIK3CB P42338 2/20 0.36
PIK3CG P48736 2/20 0.36
EPHB4 P54760 2/20 0.36
PRKDC P78527 2/20 0.36
PI4KB Q9UBF8 2/20 0.36
KAT6A Q92794 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427883 0.92 FAAH (0.48) FAAHCES2PIK3CDPDE4BKDM4E
SCHEMBL427369 0.92 FAAH (0.49) FAAHCES2PIK3CDPDE4BKDM4E
SCHEMBL424688 0.90 FAAH (0.58) FAAHCES2PIK3CDPOLBABL1
SCHEMBL427174 0.89 FAAH (0.59) FAAHCES2PIK3CDPOLBABL1
SCHEMBL427361 0.88 FAAH (0.52) FAAHCES2PDE4BKDM4ETGFBR1
SCHEMBL427411 0.87 FAAH (0.48) FAAHCES2PIK3CDPDE4BKDM1A
SCHEMBL427732 0.87 FAAH (0.53) FAAHCES2TGFBR1MTORMCHR1
SCHEMBL427871 0.86 FAAH (0.52) FAAHCES2PDE4BTGFBR1MCHR1
SCHEMBL7899710 0.85 FAAH (0.48) FAAHCES2PIK3CDPDE4BTGFBR1
SCHEMBL427345 0.85 FAAH (0.46) FAAHCES2PDE4BKDM4EMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885PIK3CD 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.